secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-275888
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica Q3 net loss $7.8M ($0.52/shr); cash $14.1M, funds into 2H 2026
--------------------------------------------------------------------------

- Net loss of $7.8M ($0.52 per share), up from $5.6M ($0.50) a year ago.
- Cash, equivalents, and short-term investments at $14.1M; expected to fund operations into 2H 2026.
- Phase 2 KOURAGE trial in AKI with respiratory failure enrollment ongoing; data expected 1H 2026.
- Positive FDA discussions on acute pancreatitis pivotal trial; final design expected 1H 2026.
- Collaboration with Telperian to leverage AI analytics for pivotal trial design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000119312525275888/0001193125-25-275888-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000119312525275888/ck0001534133-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-275888

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer